Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252876 · ClinicalTrials.gov registry record · Phase 3
GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
NCT00252876: Clinical Trial Phase 3 study, sponsored by AstraZeneca.
NCT00252876 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 2,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00252876, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.
Interventions
- DRUG tesaglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Why NCT00252876 stopped before completion
NCT00252876 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher).
The record links to 0 conditions, and to 1 intervention - of which tesaglitazar is the first listed.
NCT00252876 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00252876 about?
NCT00252876 is a clinical study titled "GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes". This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104 weeks of treatment. The total duration, including treatment and follow-up...
What is the current status of trial NCT00252876?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2005-03. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00252876?
The interventions under investigation include: tesaglitazar (DRUG).
Who is sponsoring clinical trial NCT00252876?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00252876's enrollment target sits among peer trials
2,000 100th of 2000 higher than 1,895 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia